Covid-19
The safety of our study participants and staff is our number one priority, especially during these challenging times. We’re staying on top of the latest COVID-19 developments and working to maintain the safety of everyone involved, while keeping the study on track. If you’re a participant, please contact your study site directly for the latest updates or with any questions or concerns.
What is NASH?
NASH (Non-Alcoholic Steatohepatitis) is a chronic disease caused by fat buildup and inflammation in the liver. NASH may cause liver scarring (fibrosis), which can progress to severe scarring (cirrhosis).
This can and lead to life-threatening complications including liver failure and liver cancer. NASH is often silent and asymptomatic, and can progress and develop if undiagnosed.
There are currently no approved medications for NASH, and the main treatment option is a lifestyle change, including diet and exercise. ARMOR is studying an investigational drug that aims to treat NASH and liver scarring and stop the progression of the disease.
About ARMOR
The ARMOR study is a phase 3, multinational clinical trial to evaluate the efficacy and safety of Aramchol™ for adults with NASH and liver fibrosis. The ARMOR study is a registrational clinical study, underway in 17 countries, across five continents, 200 sites and with 2000 adult subjects.
LEARN MORE >Contat Us
For patients:
armorinfo@galmedpharma.com
For Medical & Healthcare providers:
clinicaltrial@galmedpharma.com